Compare Crispr Therapeutics AG (CRSP) vs Intuit Inc. (INTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Intuit Inc. — how do they compare? Crispr Therapeutics AG trades at $51.4 (market cap $4.97B), while Intuit Inc. trades at $283.6 (market cap $77.26B). The key difference: Intuit Inc. is far larger — about 15.5× Crispr Therapeutics AG's market cap, and Intuit Inc. pays a 1.7% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | INTU | |
|---|---|---|
Market Cap | $4.97B | $77.26B |
Sector | Health | Technology |
52-Week High | $76.78 | $807.39 |
52-Week Low | $44.34 | $255.07 |
Enterprise Value | $3.32B | $75.71B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Intuit (INTU) trades at $282.43, down 2.52% over the past day, amid a wave of securities fraud investigations related to TurboTax pricing disclosures. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $12.80 versus $12.57 expected, and robust revenue growth from $18.83B in 2025 to a projected $20.9B in 2026. Technical indicators are neutral, with RSI at 55.89 and support at $278.
The outlook is mixed: analyst consensus remains bullish with a $422.88 price target and 71% buy ratings, but legal risks and a recent Goldman Sachs downgrade to sell pose near-term headwinds. Long-term growth driven by AI integration in products like Mailchimp offers upside, though investor sentiment is cautious pending legal clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →
